Greg Mayes, the new CEO of Reunion Neuroscience (TSX:REUN, Nasdaq:REUN), has a more traditional drug development background than many executives in the psychedelic space. He had a successful foray into epilepsy at a company known as Engage Therapeutics. Founded in 2017, Engage was picked up by UCB in 2020.
While Mayes’ background in pharma dates back to 2001 when he was senior counsel at AstraZeneca, his interest in Engage was more personal. “The whole reason I founded that company was because of my son’s epilepsy diagnosis,” Mayes said in a recent interview. “The most common comorbidity associated with epilepsy is depression and anxiety.”
In a recent conversation, Mayes and his colleague, Reunion’s Chief Scientific Officer Nathan Bryson, open up about the company’s strategy and how they foresee the psychedelic market evolving in the coming years.
Could you share more about what inspired you to join Reunion?…